| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 87 | 391 | 22.378 | 1.216 | 516.555 | 2.316.087 | 1.495.749 |
| Total Income - EUR | - | - | 0 | 103 | 631 | 22.379 | 1.216 | 516.555 | 2.319.162 | 1.495.959 |
| Total Expenses - EUR | - | - | 26.234 | 77.576 | 70.423 | 85.052 | 92.525 | 548.753 | 2.296.612 | 1.503.077 |
| Gross Profit/Loss - EUR | - | - | -26.234 | -77.473 | -69.792 | -62.673 | -91.309 | -32.198 | 22.551 | -7.118 |
| Net Profit/Loss - EUR | - | - | -26.234 | -77.474 | -69.798 | -62.880 | -91.321 | -36.079 | 14.192 | -7.118 |
| Employees | - | - | 5 | 7 | 5 | 7 | 6 | 6 | 6 | 7 |
Check the financial reports for the company - Bsd Pharmaceuticals Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 4.111 | 21.422 | 15.018 | 10.090 | 2.958 | 1.621 | 4.227 | 25.251 |
| Current Assets | - | - | 7.446 | 11.835 | 16.838 | 23.976 | 9.780 | 100.008 | 74.525 | 133.902 |
| Inventories | - | - | 2.612 | 2.575 | 3.664 | 3.485 | 4.699 | 76.154 | 2.093 | 30.488 |
| Receivables | - | - | 2.542 | 8.969 | 12.536 | 14.931 | 3.206 | 16.739 | 70.124 | 94.487 |
| Cash | - | - | 2.292 | 292 | 639 | 5.560 | 1.876 | 7.115 | 2.309 | 8.927 |
| Shareholders Funds | - | - | -26.191 | -103.184 | -170.984 | -230.623 | -316.830 | -353.892 | -338.627 | -344.235 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 37.747 | 136.441 | 202.840 | 264.689 | 329.568 | 455.520 | 417.379 | 503.388 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Bsd Pharmaceuticals Srl